Pharmaceuticals

PHARMABLOCK

PHARMABLOCK released FY2025 Annual Earnings on April 21 After-Market (BJT), Actual Revenue: CNY 1.974 B (Forecast: CNY 1.963 B), Actual EPS: CNY 0.88 (Forecast: CNY 0.76)

PHARMABLOCK released FY2026 Q1 earnings on April 21 After-Market (BJT), actual revenue CNY 508.03 M, actual EPS CNY 0.21

PHARMABLOCK released FY2025 Q4 earnings on April 21 After-Market (BJT), actual revenue CNY 555.42 M, actual EPS CNY 0.3038

PHARMABLOCK FY2026 Q1 Earnings Release Scheduled for April 22 After-Market BJT

PHARMABLOCK to release FY2025 earnings on April 22 After-Market (BJT), forecast revenue CNY 1.963 B, EPS CNY 0.76

Yaoke Technology sees significant increase in per share net assets in Q3, secretary explains reasons

PHARMABLOCK released FY2025 Q3 earnings on October 29 During-Market BJT, actual revenue CNY 499.33 M, actual EPS CNY 0.2013

PHARMABLOCK released FY2025 9 Months Earnings on October 29 During-Market (BJT), with actual revenue of CNY 1.419 B and EPS of CNY 0.5613

PHARMABLOCK to Release FY2025 Q3 Earnings on October 30 During-Market (BJT)

Pharsight Technology Systematically Applies AI Across Multiple Business Areas

Yaoke Technology Holds Earnings Briefing on Business Growth and Strategic Planning

Phystone Technology's Net Profit Down 26.54% in First Half of 2025

PHARMABLOCK released FY2025 Semi-Annual earnings on August 7 After-Market (BJT), actual revenue CNY 919.73 M, actual EPS CNY 0.36

PHARMABLOCK released FY2025 Q2 earnings on August 7 After-Market (BJT), actual revenue CNY 464.71 M, actual EPS CNY 0.18

PHARMABLOCK FY2025 Semi-Annual Earnings Release on August 8, 2025 (BJT)

Yaoke Technology's Stock Price Rises by 18.77%

Yaoke Technology Stock Rises, Open Securities Gives 'Buy' Rating

Yaoke Technology Holding Platform Plans to Reduce Shareholding

Director Chen Chan of MedChem Express Plans to Sell Shares

Pharmaron's stock price rises, analysts give a 'buy' rating

300725

According to the Zhitong Finance APP, PHARMABLOCK announced that the company's shareholder Ms. Zhou Quan plans to reduce her holdings in the company by no more than 2.3296 million shares through centralized bidding or block trading from September 24, 2025, to December 23, 2025, accounting for 1% of the total share capital after excluding repurchased shares

Zhitong

PHARMABLOCK shareholder Zhou Quan plans to reduce holdings by no more than 2.3296 million shares

002941

Xinjiang Communications Construction Group announced that after the market closes on September 17, "JiaoJian Convertible Bonds" will cease trading. September 22 is the last conversion day for "JiaoJian Convertible Bonds." After the market closes on that day, any "JiaoJian Convertible Bonds" that have not been converted will stop conversion. Pharmablock announced that there is only half a trading day left for the conversion of "Pharmablock Convertible Bonds." After the market closes on that day, any "Pharmablock Convertible Bonds" that have not been converted will stop conversion, and the remaining convertible bonds will be forcibly redeemed at a price of 100.62 yuan per bond. If forcibly redeemed, investors may face investment losses

XINJIANG COMMUNICATIONS CONSTRUCTION GROUP

Xinjiang Communications Construction Group convertible bonds "JiaoJian Convertible Bonds" will cease trading

300347

03347

688202

603127

06127

300363

Zhejiang Merchants Securities released a research report indicating that from Q1 2024 to Q2 2025, the revenue of leading CXO companies will increase quarter-on-quarter and year-on-year. It is expected that the year-on-year revenue growth will return to positive in Q1 2025, reaching 8.2%, and further increase to 11.6% in Q2 2025. The high level of ongoing construction projects shows that CXO companies are optimistic about capacity expansion. Overall, the performance and fundamental turning point of the CXO industry are the main driving factors

Tigermed

TIGERMED

Medicilon

JOINN

Porton

Zhejiang Merchants Securities: The growth trend of the CXO sector in 25H1 continues to improve, and the construction projects remain at a high level

Nanjing PHARMABLOCK Co., Ltd. announced that it reminds investors to pay attention to the upcoming redemption of PHARMABLOCK convertible bonds. The last trading day is September 12, 2025, and the last conversion date is September 17. Unconverted bonds will be forcibly redeemed at 100.62 yuan per bond, and investors may face losses. The company issued 11.5 million convertible bonds in 2022, with the latest conversion price at 33.61 yuan per share, reminding investors to pay attention to risks and convert within the deadline

PHARMABLOCK: PHARMABLOCK convertible bonds are about to be redeemed, reminding investors to convert their shares in a timely manner

Nanjing PHARMABLOCK Co., Ltd. announced the implementation of the redemption of PHARMABLOCK convertible bonds and the cessation of trading. The last trading day for the PHARMABLOCK convertible bonds is September 12, 2025, and the last conversion date is September 17. Those not converted will be forcibly redeemed at 100.62 yuan per bond. Investors should pay attention to the conversion rights and related risks

PHARMABLOCK reminds about the implementation of the redemption of PHARMABLOCK convertible bonds and the related trading suspension

Nanjing PHARMABLOCK Technology Co., Ltd. issued the fourteenth notice, deciding to redeem the "PHARMABLOCK Convertible Bonds" in advance on August 14, 2025. The redemption clause was triggered because the company's stock closed at least 130% of the conversion price for at least fifteen trading days within a consecutive thirty trading day period. The redemption price is 100.62 yuan per bond, with the redemption registration date on September 17 and the redemption date on September 18. The company reminds holders to pay attention to the conversion deadline and related risks

PHARMABLOCK announces the fourteenth notice of early redemption for "PHARMABLOCK Convertible Bonds"

Nanjing PHARMABLOCK Co., Ltd. issued the fifth reminder announcement for the early redemption of PHARMABLOCK convertible bonds. Due to the company's stock closing price being no less than 130% of the current conversion price of the PHARMABLOCK convertible bonds for at least fifteen trading days within a consecutive thirty trading day period, the conditional redemption clause has been triggered. The redemption price is 100.62 yuan per bond, with the redemption registration date set for September 17, 2025, and the redemption date on September 18. This redemption will be a full redemption, and after completion, the PHARMABLOCK convertible bonds will be delisted from the Shenzhen Stock Exchange

PHARMABLOCK released the fifth reminder announcement for the early redemption of PHARMABLOCK convertible bonds

PHARMABLOCK has systematically laid out AI applications in multiple business areas, generating over 80 million novel molecular building blocks to solve structural optimization challenges in new drug design. The company strengthens the collaboration between process development and intelligent teams, utilizing machine learning models to optimize the R&D process. In the future, it will deepen AI investment and promote the deployment of fully automated laboratories and robotic equipment

PHARMABLOCK has systematically laid out AI applications in multiple business areas

According to the Zhitong Finance APP, PHARMABLOCK released its semi-annual report for 2025, reporting an operating income of 920 million yuan, a year-on-year increase of 23.48%. The net profit attributable to shareholders of the listed company was 72.4981 million yuan, a year-on-year decrease of 26.54%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 59.6211 million yuan, a year-on-year decrease of 11.82%. The basic earnings per share were 0.36 yuan

PHARMABLOCK released its performance for the first half of the year, with a net profit attributable to the parent company of 72.4981 million yuan, a decrease of 26.54%

603456

300149

300683

The concept of CRO/CMO has experienced a volatile surge, with ChemPartner hitting the "20cm" limit up, followed by gains in PHARMABLOCK, HITECK, Jiuzhou Pharma, Tigermed, JOINN, and Nossan

Jiuzhou Pharma

ChemPartner

HITECK

CRO/CMO concept experiences a volatile surge, ChemPartner hits the "20cm" limit up

PHARMABLOCK(300725.SZ)